The U.S. Food and Drug Administration (FDA) approved Zepbound for the treatment of obesity in November 2023. Some prescribe ...
A late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings ...
Tirzepatide, the main ingredient in the injected weight loss and diabetes drugs Zepbound and Mounjaro , might help reduce obstructive sleep apnea symptoms, preliminary results from two late-stage ...
Eli Lilly’s weight loss drug Zepbound has been shown to “significantly reduce” obstructive sleep apnea (OSA) in adults with obesity, the company said Wednesday. Injections of tirzepatide ...
Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday.Based on results from trials in people with sleep apnea, the ...
Weight loss drugs like Ozempic and Mounjaro have gained great traction in recent months, and now drugmakers have found another benefit of the popular medications. Eli Lilly, the manufacturer of ...
Tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced sleep apnea symptoms for people with obesity. The drug improved sleep apnea symptoms whether or not people used a PAP machine.
Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said in a release Wednesday. Obstructive sleep apnea affects about 39 ...